Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Amanda Lind

Nurse Practitioner Pittsburgh, PA Nurse Practitioner

NPI 1841931748 CMS profile 11367897

1350 Old Freeport Rd Ste 1A, Pittsburgh, PA 15238

Open in the dashboard

General payments

$1,711

84 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Lind of Pittsburgh, PA is reported in the CMS Open Payments database as having received $1,711 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $242 12
2024 General $468 21
2023 General $495 24
2022 General $506 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Lind
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Amanda Lind were reported at $242. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Amanda Lind Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $506 $152 $48–$470 $149
2023 $495 $166 $54–$529 $160
2024 $468 $173 $55–$556 $164
2025 $242 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $437 18 payments
  2. Alkermes, Inc. $257 12 payments
  3. Otsuka America Pharmaceutical, Inc. $229 12 payments
  4. ITI, Inc. $169 7 payments
  5. Lundbeck LLC $94 5 payments
  6. Axsome Therapeutics, Inc. $92 6 payments
  7. Neurocrine Biosciences, Inc. $73 4 payments
  8. Janssen Pharmaceuticals, Inc $68 4 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $65 4 payments
  10. Sunovion Pharmaceuticals Inc. $65 4 payments
  11. Other $163 8 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,662 83 payments
  2. Education $49 1 payment
Products named General payments · program years 2022–2025
  1. VRAYLAR Neuroscience $292 12 payments
  2. LYBALVI Cns $213 10 payments
  3. LYBALVI Cns $213 10 payments
  4. LYBALVI Cns $213 10 payments
  5. LYBALVI Cns $213 10 payments
  6. REXULTI Psychiatry $188 10 payments
  7. VRAYLAR Neuroscience $145 6 payments
  8. CAPLYTA $131 5 payments
  9. REXULTI Psychiatry $94 5 payments
  10. Auvelity $92 6 payments
  11. Other $579 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

2,720

Median for Nurse Practitioner: 389

Drug cost

$391,893

Median for Nurse Practitioner: $21,885

Branded share of claims

22.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 28 $227,718
Rexulti Brexpiprazole Brand 24 $35,101
Lybalvi Olanzapine/Samidorphan Malate Brand 19 $30,759
Auvelity Dextromethorphan Hbr/Bupropion Brand 20 $22,360
Lisdexamfetamine Dimesylate Generic 35 $9,689
Chlorpromazine Hcl Generic 13 $9,322
Bupropion Xl Bupropion Hcl Brand 179 $8,024
Vyvanse Lisdexamfetamine Dimesylate Brand 14 $5,080
Aripiprazole Generic 126 $4,546
Venlafaxine Hcl Er Venlafaxine Hcl Brand 91 $4,166

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 1 billing codes

Paid by Medicare

$1,728

Medicare's payments for the services billed

Medicare patients

16

Average age 59

Services billed

23

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Atrial fibrillation 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $105
$105 — —
REXULTI
  • Lundbeck LLC $57
  • Otsuka America Pharmaceutical, Inc. $42
$99 24 —
LYBALVI
  • Alkermes, Inc. $52
$52 19 —
VIVITROL
  • Alkermes, Inc. $44
$44 — —
CAPLYTA
  • ITI, Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record